IRMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IRMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-29), iRadimed's current share price is $40.90. iRadimed's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.63. iRadimed's Cyclically Adjusted Price-to-FCF for today is 64.92.
The historical rank and industry rank for iRadimed's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, iRadimed's highest Cyclically Adjusted Price-to-FCF was 87.26. The lowest was 47.90. And the median was 68.44.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
iRadimed's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $0.257. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.63 for the trailing ten years ended in Dec. 2023.
The historical data trend for iRadimed's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRadimed Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 48.43 | 67.86 | 79.04 | 72.07 | 75.33 |
For the Medical Devices subindustry, iRadimed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where iRadimed's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
iRadimed's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 40.90 | / | 0.63 | |
= | 64.92 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRadimed's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, iRadimed's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.257 | / | 129.4194 | * | 129.4194 | |
= | 0.257 |
Current CPI (Dec. 2023) = 129.4194.
iRadimed Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | 0.044 | 99.695 | 0.057 |
201406 | 0.149 | 100.560 | 0.192 |
201409 | 0.084 | 100.428 | 0.108 |
201412 | -0.083 | 99.070 | -0.108 |
201503 | 0.085 | 99.621 | 0.110 |
201506 | 0.132 | 100.684 | 0.170 |
201509 | 0.183 | 100.392 | 0.236 |
201512 | 0.184 | 99.792 | 0.239 |
201603 | 0.158 | 100.470 | 0.204 |
201606 | 0.069 | 101.688 | 0.088 |
201609 | 0.276 | 101.861 | 0.351 |
201612 | 0.156 | 101.863 | 0.198 |
201703 | -0.040 | 102.862 | -0.050 |
201706 | 0.010 | 103.349 | 0.013 |
201709 | 0.141 | 104.136 | 0.175 |
201712 | 0.107 | 104.011 | 0.133 |
201803 | 0.130 | 105.290 | 0.160 |
201806 | 0.121 | 106.317 | 0.147 |
201809 | 0.055 | 106.507 | 0.067 |
201812 | 0.281 | 105.998 | 0.343 |
201903 | 0.047 | 107.251 | 0.057 |
201906 | 0.198 | 108.070 | 0.237 |
201909 | 0.247 | 108.329 | 0.295 |
201912 | 0.301 | 108.420 | 0.359 |
202003 | 0.078 | 108.902 | 0.093 |
202006 | 0.050 | 108.767 | 0.059 |
202009 | 0.098 | 109.815 | 0.115 |
202012 | 0.191 | 109.897 | 0.225 |
202103 | 0.061 | 111.754 | 0.071 |
202106 | 0.271 | 114.631 | 0.306 |
202109 | 0.250 | 115.734 | 0.280 |
202112 | 0.252 | 117.630 | 0.277 |
202203 | 0.079 | 121.301 | 0.084 |
202206 | 0.096 | 125.017 | 0.099 |
202209 | 0.268 | 125.227 | 0.277 |
202212 | 0.203 | 125.222 | 0.210 |
202303 | -0.151 | 127.348 | -0.153 |
202306 | 0.246 | 128.729 | 0.247 |
202309 | 0.075 | 129.860 | 0.075 |
202312 | 0.257 | 129.419 | 0.257 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of iRadimed's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Roger E. Susi | director, 10 percent owner, officer: CEO, President, Chairman | C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708 |
James B Hawkins | director | C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708 |
Anthony Vuoto | director | |
Monty K Allen | director | |
Hilda Frederique Scharen-guivel | director | 440 PALM ISLAND SE, CLEARWATER BEACH FL 33767 |
John Glenn | officer: Chief Financial Officer | 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577 |
Christopher K. Scott | officer: CHIEF FINANCIAL OFFICER & SECR | C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708 |
Brent Johnson | officer: Exec. VP. Sales & Marketing | 4900 HOPYARD RD, SUITE 210, PLEASITAN CA 94588 |
Steven M. Nardi | officer: VP MANUFACTURING | C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708 |
Louis S. Waldman | officer: CONTROLLER | C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708 |
Leslie L Mcdonnell | director, officer: Chief Exec Officer & Director | 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Francis X. Casey | officer: VP OF REG AND QUAL ASSURANCE | C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708 |
John K Mccreery | officer: Chief Operating Officer | IRADIMED CORP, 1025 WILLA SPRINGS BLVD, WINTER SPRINGS FL 32708 |
Jonathan Kennedy | director | INTERSIL CORPORATION, 1001 MURPHY RANCH ROAD, MILPITAS CA 95035 |
Serge Novovich | director | C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-15-2022
By GuruFocus Research GuruFocus Editor • 01-19-2023
By GlobeNewswire GlobeNewswire • 07-22-2022
By sperokesalga sperokesalga • 02-24-2023
By Marketwired • 08-03-2023
By Marketwired • 09-06-2023
By sperokesalga sperokesalga • 05-10-2023
By sperokesalga sperokesalga • 04-27-2023
By Marketwired • 10-26-2023
By GuruFocus Research • 12-16-2023